Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02715752 · ClinicalTrials.gov registry record
A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin
A clinical trial of Cytomegalovirus Infections and Human Papillomavirus, sponsored by The Center for the Biology of Chronic Disease.
- Completed
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT02715752 is a study of Cytomegalovirus Infections and Human Papillomavirus that has completed, run by The Center for the Biology of Chronic Disease. The registered enrollment target is 1,000 participants, above the 161-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (521% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02715752, a study of Cytomegalovirus Infections and Human Papillomavirus, has completed, sponsored by The Center for the Biology of Chronic Disease.
- COMPLETED
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This study measured the changes in health-related complaints by analyzing charts of individuals, who are infected with a latent virus, who have used Gene-Eden-VIR/Novirin.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Gene-Eden-VIR/Novirin
Study Locations (1)
New York
- The Center for the Biology of Chronic Disease - Valley Cottage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2016-01 |
| Est. Completion | 2016-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02715752
The ClinicalTrials.gov registry entry for NCT02715752 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 161-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (521% higher). The listed sponsor is The Center for the Biology of Chronic Disease, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Cytomegalovirus Infections appearing as the primary indexed condition, and to 1 intervention - of which Gene-Eden-VIR/Novirin is the first listed.
NCT02715752 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02715752 about?
NCT02715752 is a clinical study titled "A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin". This study measured the changes in health-related complaints by analyzing charts of individuals, who are infected with a latent virus, who have used Gene-Eden-VIR/Novirin.
What is the current status of trial NCT02715752?
This trial is currently completed. The enrollment target is 1,000 participants. The study started on 2016-01. Estimated completion is 2016-03.
What conditions does trial NCT02715752 study?
This clinical trial studies the following conditions: Cytomegalovirus Infections, Human Papillomavirus, Epstein-Barr Virus Infections, Varicella Zoster Virus Infection, Herpes Simplex Infections.
What interventions are being tested in trial NCT02715752?
The interventions under investigation include: Gene-Eden-VIR/Novirin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02715752?
This trial is sponsored by The Center for the Biology of Chronic Disease, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02715752 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegalovirus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
RECRUITING · Phase 4
-
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
RECRUITING · Phase 2
-
Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study
RECRUITING
-
R-MVST Cells for Treatment of Viral Infections
RECRUITING · Phase 1
-
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
RECRUITING · Phase 1
-
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.